

DRUG UTILIZATION REVIEW BOARD
October 20, 2021
MO HealthNet (MHD)
VIA WEBEX ONLY

Committee Members Present:

Charlene Heyde, RPH
Sandra Bollinger, PharmD
Julie Ferguson, DO
Lisa Pierce, MD
Jennifer Passanise, FNP
Stacy Mangum, PharmD
Ginger Nicol, MD, CEDS
Kim Eisenstein, MD

Committee Members Absent:

Susan Abdel-Rahman, PharmD, Chair
Rick Kegler, PharmD, MBA

MO HealthNet Staff Present:

Joshua Moore, PharmD, Director of
Pharmacy
Mark Roaseau, R.Ph, Clinical Pharmacist
Angela Wilson, Pharmacy Operations
Manager
Elizabeth Sissom, RN, Clinical
Management
Lisa E. Smith, Program Development
Specialist
Carmen Burton, Administrative Assistant
Timothy Kling, MD, Acting Medical
Director
Elizabeth Short, Program Development
Specialist
Connie Sutter, Fiscal Manager

Olivia Rush, PharmD, Program Integrity
Pharmacist

Contractors in Attendance:

April Ash, PharmD, Conduent
Blake Shrouf, PharmD, AAHIVP,
Conduent
Jennifer Colozza, PharmD, Conduent
Karen Powell, PharmD, Conduent
Katie Wilbers, PharmD, Conduent
Luke Boehmer, PharmD, Conduent
Megan Fast, PharmD, Conduent
Sandra Kapur, PharmD, Conduent
Serena Barden, PharmD, BCPS,
Conduent
Geri Roling, RN, Wipro
Valerie Schmitz, RN, BSN Wipro
Paul Fung, PharmD, Conduent

Others Attending:

A Hailes
Alex Bitting
Brooke Wilkins
Camille Kerr
Carrie Davis
Charles Trebilcock
Deb Profant
Folger Tuggle
Gina Heinen

Henrio Thelemaque
James Baumann
Jeff Knappen
Jenny Carrell
Jill Frandeen
Jim Fleming
Joe Payne
Kaholt
Karen Malamut
Kurt Hendrickson
Mandy Schnelten
Mark Kaiser
Melissa Basil
Michele Shirley
Phillip King
Ricki Roberson
Roberto Pedraza
Robin Sherman
Suzzane Tiller
Tami Sova
Teresa Blair
Terry McCurren
Tina Rhinehart
Tom Guyer

<p>Welcome, Introductions and Opening Remarks</p>	<p>Stacy Magnum stepped in as interim chair for Susan Abdel-Rahman, Board Chair, and called the meeting to order.</p> <p>Joshua Moore, MHD Director of Pharmacy, introduced himself and facilitated the meeting on behalf of the MO HealthNet Division.</p>
<p>Minutes Review</p>	<p>Discussion: Minutes were reviewed from the July 2021 meeting.</p> <p>Decision: The committee voted to accept these approved minutes with no revisions.</p>
<p>Pharmacy Program and Budget Update</p>	<p>Elizabeth Short and Joshua Moore presented a brief power point of the Pharmacy Program and Budget Updates. Information presented included:</p> <ul style="list-style-type: none"> - July- Sept 2021 Eligibles by Group - July- Sept 2021 Expenditures by Enrollment Group - July- Sept 2021 Expenditures by Service - FY22 Pharmacy Spend vs July-Sept 2021 Total Medicaid Spend - FY22 Pharmacy Expenditures - Top 4 Drug Classes per FY22 - Pharmacy Expenditures/Eligibles per FY (2015 – 2021) - Hep C Spend and Utilization FY18 – FY22 - Synagis Expenditures FY19 – FY22 - FY19 – FYTD22 Rare Disease Expenditures - Streamlining older edits to help decrease call volume to the helpdesk and overall enhanced workflow for all those involved - Diagnosis code requirements - Updates to opioid policy will be forthcoming at the December DPAC meeting - Pharmacist Provider Services – rule making process and hoping for state fiscal year 2023 implementation - Out of State Pharmacies updates

Old Business	
Old Business	<p>Joshua Moore discussed the Edit Implementation Schedule and the criteria for Previously Approved Clinical Edits, Step Therapies and Prior Authorizations.</p> <p>These handouts were also provided to all attendees and will be posted to the Division's web page: https://dss.mo.gov/mhd/cs/advisory/drugpa/meeting.htm</p>
New Business	
New Drug Review	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore reviewed the new products identified for the quarter and the recommended status within the pharmacy program. <ul style="list-style-type: none"> o A listing of products recommended for open access, clinical edit, preferred drug list (PDL), or continue prior authorization was emailed to the Board for discussion and action. o No public commit provided. <p>Decision: The committee voted to accept the presented new drug recommendations with no revisions.</p>
Clinical & Fiscal Edits With No Annual Changes	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edits for discussion to the Board which included: <ul style="list-style-type: none"> o Emsam Clinical Edit o Immunoglobulin Clinical Edit o Lambert-Eaton Myasthenic Syndrome (LEMS) Clinical Edit o Neuromyelitis Optica Spectrum Disorder (NMOSD) Clinical Edit o Nuedexta Clinical Edit o Oxandrin Clinical Edit o Palforzia Clinical Edit o Ranexa Clinical Edit o Xcopri Clinical Edit - No public commit provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p align="center">Aduhelm Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Questions arose around the restriction to the diagnosis of early Alzheimer’s disease; it was explained that the study population did include moderate to severe Alzheimer’s disease. - Discussion arose around the FDA board reviewer’s resignation; it was explained that the manufacturers have a signed rebated agreement with CMS, we are required to cover the medication. - Questions arose around an upper age cutoff; it was explained that MHD normally does not cover patients over the age of 65, as they should fall under Medicare coverage. - Public comment provided by: <ul style="list-style-type: none"> o Tami Sova with Biogen yielded her time back <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Botulinum Toxin Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Equetro Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Narcolepsy Inhibitors Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Deb Profant with Jazz Pharmaceuticals <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Psychotropic Medications Polypharmacy Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Serotonin and Norepinephrine Reuptake Inhibitors (SNRI) Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Selective Serotonin Reuptake Inhibitor (SSRI) Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Questions arose around the diagnosis list mentioned in the proposal – it was explained that the list was too extensive to include on the proposal - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Transthyretin-Mediated Amyloidosis (ATTR) Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Alex Bitting with Alnylam Pharmaceuticals on Onpattro <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p align="center">Preferred Drug List Edits With No Annual Changes</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edits for discussion to the Board which included: <ul style="list-style-type: none"> o ARBs and ARBs/Diuretic Combinations o ARBs/CCB Combinations o Calcium Channel Blockers, Dihydropyridine o Calcium Channel Blockers, Non-Dihydropyridine o Direct Renin Inhibitors and Combinations o Dry Eye Disease Agents o Niacin Derivatives o PAH, ETRAs o PAH, Prostacyclins Inhaled o PAH, Prostacyclins Oral o Sympatholytics - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">ACE Inhibitors and ACE Inhibitors/Diuretic Combinations</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">ACE Inhibitors/Calcium Channel Blocker Combinations</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">ADHD, Methylphenidate Short Acting</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Discussions arose on the need for prescribers to submit actual scale vs score documented within the note ; MHD to take back and potentially change workflow habits of helpdesk - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p align="center">ADHD, Amphetamines Short Acting</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Discussions arose on the need for prescribers to submit actual scale vs score documented within the note ; MHD to take back and potentially change workflow habits of helpdesk - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">ADHD, Methylphenidate Long Acting</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Discussions arose on the need for prescribers to submit actual scale vs score documented within the note ; MHD to take back and potentially change workflow habits of helpdesk - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">ADHD, Amphetamines Long Acting</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Discussions arose on the need for prescribers to submit actual scale vs score documented within the note ; MHD to take back and potentially change workflow habits of helpdesk - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">ADHD, Non-Stimulants</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Anticoagulants</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Anticonvulsants, Rescue Agents</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Antiplatelets</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Positive discussion on removal of barriers in helping participants receive medications to prevent hospitalizations. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Beta Blockers and Beta Blockers/Diuretic Combinations</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Homozygous Familial Hypercholesterolemia (HoFH) Agents</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Questions arose on the appropriate LDL levels required for use of therapy along with the need for genetic testing for diagnosis. - Public comment provided by: <ul style="list-style-type: none"> o Tracy Pellegrino with Regeneron Pharmaceuticals on Evkeeza <p>Decision: The Board voted to table the recommended criteria due to the need of a further review of the appropriate LDL levels and need for genetic testing for diagnosis.</p>
<p>PAH, PDE5/SGC Stimulators</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>PAH, Prostacyclins Injectable</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>PCSK9 Inhibitors</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Proton Pump Inhibitors</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Statins (HMG-CoA Reductase Inhibitors) and Combinations</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Discussion arose around the naming convention of edit now that ezetimibe is preferred and is not a statin. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Triglyceride Lowering Agents</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Preferred Drug List Announcement</p>	<p>A handout of therapeutic categories to be reviewed for inclusion on the Preferred Drug List for the next phase and December meeting was included in the meeting packet.</p> <p>This handout was also provided to all attendees and will be posted to the Division's web page: https://dss.mo.gov/mhd/cs/advisory/drugpa/meeting.htm</p>
<p>Program Utilization Information – Conduent Update</p>	<p>Jennifer Colozza with Conduent presented the following items for review:</p> <ul style="list-style-type: none"> - Top 25 Drugs by Paid Amount 4th Quarter 2021 (April, May, June) - Top 25 Drugs by Paid Number 4th Quarter 2021 (April, May, June) - Call Center User Statistics August 2021 - CyberAccess Logging Information - New Drug Statistics August 2021
<p>DUR Interventions – Conduent Update</p>	<p>Katie Wilbers with Conduent presented the following items for review:</p> <ul style="list-style-type: none"> - Recent Interventions: <ul style="list-style-type: none"> o Anticonvulsant Drug Use Evaluation – to be mailed soon o Glucagon after visit for Hypoglycemia – mailed June 2021 - Potential RetroDUR Interventions: <ul style="list-style-type: none"> o CNS Depressant without Naloxone o Long-Term use of Opioids and Benzodiazepines - Outcomes: <ul style="list-style-type: none"> o PTSD o High Risk Influenza – mailed October 2020
<p>Adjournment</p>	<p>Kimberly Eisenstein motioned for the meeting to be adjourned. The meeting was adjourned pursuant to Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees. The next meeting of the Drug Utilization Review Board is scheduled via hybrid meeting (in person and WebEx) on Wednesday, January 19, 2022.</p>

Roll Call for October 20, 2021				
	<u>Action Item</u>			
<u>Board Member</u>	July Meeting Minutes	All Recommendations: Block Vote for CE, FE and PDL Edits	Closing	Adjournment
Susan Abdel-Rahman	A	A	A	A
Charlene Heyde	Y	Y	A	A
Sandra Bollinger	Y	Y; N for Aduhelm CE	Y	Y
Julie Ferguson	Y	Y	Y	Y
Lisa Pierce	MY	MY	SY	MY
Jennifer Passanise	Y	Y	Y	Y
Stacy Mangum	Y	Y	Y	Y
Ginger Nicol	Y	A	Y	Y
Rick Kegler	A	A	A	A
Kim Eisenstein	SY	SY	MY	SY

Roll Call Abbreviations: A-Absent; AL-Alternate; R-Ratify; M-Motion; S-Second; Y-Yes; N-No; AB-Abstain